Strategies based on this rationale are the beta-2-microglobulin (B2M) Antibody-Drug Conjugate (ADC), whose efficacy has been tested in vitro in colon and bladder cancer cell lines, and the apolipoprotein D ADC tested in senescent skin fibroblasts both in vitro and in vivo231. The gene discussed is B2M; the disease is urinary bladder carcinoma.